SHANGHAI – Executives from Eli Lilly and Co., and multifunctional contract research organization (CRO) Wuxi Apptec came together at the Shangri-la Hotel Pudong to tout a strategic collaboration to develop a phase I, small-molecule drug that could treat cardiovascular (CV) patients with dyslipidemia. The deal, which first went public four months ago, was receiving an extra communications push, a sign of the changing times in China.